The U.S. Food and Drug Administration on Friday approved Pfizer Inc's nasal spray for migraine, giving patients access to a potentially fast-acting pain-relief option for headaches.
"The drug has two main advantages over the older CGRP antagonists: it is safe for people with cardiovascular risk factors, and second, it does not cause medication overuse headache," said Dr Emad Estemalik, psychiatrist at Cleveland Clinic.Pfizer is hoping to gain a competitive edge in the migraine drug category with Zavzpret, which Biohaven has called the "Epipen of migraine", for its quick action.
Zavzpret's approval was based on late-stage study data that showed the drug was superior in 13 of 17 goals when compared to placebo, including pain relief in 15 minutes and normal function at 30 minutes. About 39 million people in the United States suffer from migraine, according to the Migraine Research Foundation.Reporting by Khushi Mandowara and Bhanvi Satija in Bengaluru; Editing by Anil D'Silva, Vinay Dwivedi and Shinjini Ganguli
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer wins FDA approval for its migraine nasal sprayPfizer Inc. said Friday the U.S. Food and Drug Administration has approved its migraine nasal spray Zavzpret. The treatment is the first and only calcitonin...
Read more »
FDA approves Pfizer's new nasal spray treatment for migrainesThe FDA approved Pfizer's newest drug on the migraine market, Zavzpret (zavegepant), the first and only migraine treatment offered in a nasal spray.
Read more »
US FDA approves Pfizer's pain-relief nasal spray for migraineThe U.S. Food and Drug Administration on Friday approved Pfizer Inc's nasal spray for migraine, giving patients access to a potentially fast-acting pain-relief option for headaches.
Read more »
Utah Food Bank expects increased demand as boost to food stamps endsThe Utah Food Bank is gearing up for more demand for assistance after boosted food stamp benefits ended in February.
Read more »
FDA Approves Amphastar Pharma's Nasal Spray for Opioid OverdoseAmphastar Pharmaceuticals Inc said on Wednesday the FDA had approved its nasal spray for emergency treatment of known or suspected opioid overdose.
Read more »
FDA approves nasal spray for migraines that may relieve symptoms within 30 minutesTh FDA approved Zavegepant, sold under the brand name Zavzpret, after studies showed it more effective than a placebo at treating migraine symptoms within 30 minutes and up to 48 hours later. FDA approves migraine nasal spray that works in minutes
Read more »